An Air India pilot allegedly allowed a woman friend inside the cockpit of the flight. The case was registered with the AI and the DCGI, after a cabin crew filed a complaint citing violation of safety norms. The accused pilot also asked the cabin crew to make a welcoming, warm and comfortable arrangement for his woman friend. After the incident, the AI issued a statement and assured strict action.
Bharat Biotech International Ltd (BBIL) on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for its intranasal COVID-19 vaccine, announced Union Health Minister Mansukh Mandaviya. With this, Bharat Biotech's intranasal COVID-19 vaccine will be India's first nasal vaccine for the deadly virus in India. The approval came after the Bharat Biotech completed the third and final trial of the drug, used for… read-more
In the National Capital of Delhi, one Drug Controller General of India (DCGI) official was arrested by CBI for allegedly taking a bribe of Rs 4 lakh, on June 21. Along with Joint Drugs Controller (JDC) Eswara Reddy, Dinesh Dua, Director of a Delhi-based private company was also apprehended. The duo was allegedly accepting the bribe to waive off the phase III clinical trial of Insulin Aspart injection.
The Drugs Controller General of India granted Emergency Use Authorization (EUA) of two doses of ZyCoV-D, a COVID-19 vaccine for children above 12 years old. Manufactured by Zydus Lifesciences limited, the vaccine was used in three doses, for 0,28, and 56 days. However, with the recent approval, ZyCoV-D would now be used in two doses, with a gap of 0-28 days. With this, vaccination time required will be reduced.
The Drugs Controller General of India (DCGI) approved the two vaccines Covaxin and Corbevax for children under 12 in India, against COVID-19. While Bharat Biotech's Covaxin has been approved for 6 to12-year-old, Biological E's Corbevax will be used as Emergency Use Authorization (EUA) for 5 to12-year-old kids in India. The approval was based on the Subject Expert Committee's recommendation report, which was prepared as per trials of the… read-more
The Subject Expert Committee (SEC) or the Drugs Controller General of India (DCGI) recommended the Corbevax COVID-19 vaccine for children between the 5 to 12-year-old age group. On April 21, the government panel said the vaccine is effective in children and has been recommended after trials. Furthermore, the final approval for the emergency use authorization (EUA) of Corbevax would be given by the DCGI soon.
Amid COVID-19 pandemic, India is to have Nitric Oxide Nasal Spray, for adults having the infection. Launched on February 9 by Glenmark Pharmaceutical, the spray would be for adults, contracting the virus, with high-risk of progression of the disease. The medicine has been launched under FabiSpray brand in India. In July 2021, Glenmark proposed the nasal Spray, which later got approved by the Drugs Controller Genera of India (DCGI).
Human trials of mRNA vaccine against COVID-19's new variant Omicron is to begin from February. Notably, Pune-based Gennova Biopharmaceutical made mRNA vaccine and completed phase I and II trials and submitted a report to the Drugs Controller General of India (DCGI). Along with it, the company also submitted a data of Phase III trials and are waiting for their approval from the Vaccine Subject Expert Committee (SEC).
Courtesy: The Times Of India
The Director Controller General of India (DCGI) approved India made RT-PCR kit to detect new COVID-19 variant "Omicron". On January 5, ICMR General Director Dr Balram Bhagava said, the new RT-PCR kit has been manufactured by Tata MD and ICMR, to test Omicron. "This kit test will give results in four hours," said Dr. Bhagava. Meanwhile, in India, there are a total of 2,135 Omicron cases.
The Director Control General of India (DCGI) approved phase III trial of Intranasal COVID-19 vaccine, manufactured by Bharat Biotech. On January 4, the Subject Expert Committee (SEC) of the DCGI, approved the report, following which phase III trail will begin on 5,000 subject, 50% Covishield vaccinated people and 50% COVAXIN vaccinated people. If successful, the Intranasal vaccine will be used as booster shot, especially when nation is facing… read-more
Courtesy: One India